卵巢癌的全腹放射治疗。
Whole abdominal radiotherapy in ovarian cancer.
作者信息
Biete Alberto, Valduvieco Izaskun, Rovirosa Angels, Farrús Blanca, Casas Francesc, Conill Carlos
机构信息
Department of Radiation Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
出版信息
Rep Pract Oncol Radiother. 2010 Mar 23;15(2):27-30. doi: 10.1016/j.rpor.2010.02.004. eCollection 2010.
OBJECTIVES
The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.
MATERIAL AND METHODS
Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40-70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10). The total radiation dose was 22.5 Gy in the whole abdomen and 42-45 Gy in the pelvis.
RESULTS
The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS) was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The sites of recurrence were the abdomen in 2 patients and distant metastases in the other 2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.
CONCLUSIONS
Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.
目的
本研究旨在评估卵巢癌患者接受辅助性全腹放疗（WART）后的临床结局和毒性反应。
材料与方法
10例卵巢癌患者接受了WART及辅助化疗（9/10），这些患者均为最佳肿瘤细胞减灭术患者，平均年龄58岁（40 - 70岁），其中Ⅰc期4例，Ⅱ期2例，Ⅲ期4例。全腹总辐射剂量为22.5 Gy，盆腔为42 - 45 Gy。
结果
平均随访8年。5年无病生存率（DFS）为60%，总生存率（OS）为70%。4例患者疾病复发。复发部位为：2例患者为腹部复发，另外2例患者为远处转移（肝转移和脑转移）。胃肠道毒性反应如下：急性毒性反应3/10为Ⅰ级和Ⅱ级，晚期毒性反应2/10为Ⅰ级和Ⅱ级，仅有1例患者发生小肠梗阻（SBO），需要手术治疗。
结论
术后全腹放疗联合铂类化疗可实现较高的局部区域疾病控制率，且急性毒性风险可接受。
Zotero 插件